NCT05199584已完成2 期
A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 16
- 主要终点
- Objective Response Rate (ORR)
研究概览
简要总结
This study employs a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF) mutations in the Patched-1 (PTCH1) gene. Stage 1 of this study will enroll approximately 44 patients randomized between two dose levels. As appropriate, Stage 2 of the study will expand enrollment based on the results of Stage 1.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Females or males greater than or equal to 18 years of age. If under 18 years of age, males must have a bone age of at least 17 years and females must have a bone age of at least 15 years. X-rays will be reviewed by a qualified physician (e.g. radiologist or endocrinologist) for eligibility for those under 18 years of age
- •Has histologically or cytologically confirmed solid tumor that harbors a PTCH1 loss of function mutation, identified via genomic sequencing routinely performed at a CLIA certified laboratory
- •Able to take medication orally
- •Patients must be refractory to all standard of care therapy, or standard or curative therapy does not exist, or the patient has documented their refusal of standard of care therapies
- •Patients willing to sign and have a full understanding of the informed consent form
- •Life expectancy of ≥ 3 months
排除标准
- •Concurrent administration of any anti-cancer therapies (e.g., chemotherapy, other targeted therapy) other than those administered in this study
- •Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures. Patients with indwelling catheters are allowed
- •Malignancies other than the primary tumor type within 5 years prior to study start, with the exception of those with a negligible risk of metastasis or death (e.g., expected 5-year Overall Survival > 90%) treated with expected curative outcome (e.g., in situ melanoma, basal or squamous cell skin cancer if completely excised, localized prostate cancer that is managed by surveillance, ductal carcinoma in situ treated surgically with curative intent are allowed)
- •History of clinically significant autoimmune disease requiring prescription systemic therapy in the last two years prior to study start; patients with controlled hypothyroidism may be considered after evaluation by the Investigator.
- •Presence of active infection at study start or confirmed active human immunodeficiency virus (HIV), Hepatitis B virus (HBV), or Hepatitis C virus (HCV)
- •Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within 3 months prior to study start, unstable arrhythmias, or unstable angina. Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or left ventricular ejection fraction < 50% must be on a stable medical regimen that is optimized in the opinion of the treating physician
- •Refractory nausea and vomiting, malabsorption, external biliary shunt or significant bowel resection that would preclude adequate absorption of investigational product
- •Major surgical procedure within 28 days prior to study start or anticipation of need for a major surgical procedure during the course of the study
- •Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within 28 days prior to study start
- •Use of drugs that are known moderate or stronger CYP3A4 inhibitors or inducers within 12 days prior to study start
- •Unresolved toxicity of ≥ CTCAE Grade 2 attributed to any prior therapies (excluding anemia, alopecia, skin pigmentation, platinum-induced neurotoxicity and endocrine disease or ailments that are stable)
- •Males and females of reproductive potential who are sexually active and unwilling to use birth control for the duration of the study and for 3 months after their final study dose
- •Females that are pregnant or nursing
- •Females and males that are unwilling to refrain from blood or blood product donation for the duration of the study and for 30 days after their final study dose
- •Males who are unwilling to refrain from sperm donation and females who are unwilling to refrain from egg donation for the duration of the study and for 3 months after their final study dose
- •Patients with a history of a severe allergic reaction, anaphylactic reaction or known hypersensitivity to any component of ENV-101
- •Patients who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with a study investigative site or the study Sponsor
研究组 & 干预措施
200 mg ENV-101
Experimental
ENV-101 (taladegib) tablets, 200 mg once-daily in 28-day cycles
干预措施: ENV-101 (taladegib) (Drug)
300 mg ENV-101
Experimental
ENV-101 (taladegib) tablets, 300 mg once-daily in 28-day cycles
干预措施: ENV-101 (taladegib) (Drug)
结局指标
主要结局
Objective Response Rate (ORR)
时间窗: through study completion, an average of 6 months
ORR is comprised of Complete Response (CR) and Partial Response (PR), measured by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1), as determined by an independent review (confirmed CR or PR will be defined as a repeat assessment performed no less than 28 days after the criteria for response is first met).
次要结局
- Clinical Benefit Rate (CBR)(through study completion, an average of 6 months)
- Duration of Response (DOR)(through study completion, an average of 6 months)
- Change in steady-state exposure to study medication(From Baseline through study completion, an average of 6 months)
- Frequency of Adverse Events (AEs)(through study completion, an average of 6 months)
- ORR by Investigator(through study completion, an average of 6 months)
- Change in Gli1 inhibition(From Baseline through study completion, an average of 6 months)
- Frequency of unacceptable toxicities(through study completion, an average of 6 months)
- Overall Survival (OS)(through study completion, an average of 6 months)
- Progression Free Survival (PFS)(through study completion, an average of 6 months)
研究者
研究点 (16)
Loading locations...
相似试验
已完成
不适用
To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid TumorsNCT05014828BeiGene58
已完成
不适用
A multicenter phase II study assessed safety and efficacy of asunaprevir and daclatasvir in patients with chronic hepatitis C virus genotype 1 infection and end-stage renal disease requiring hemodialysisChronic hepatitis C with end-stage renal disease requiring hemodialysisJPRN-UMIN000015882Saga Study Group of Liver Diseases25
进行中（未招募）
2 期
Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)Hodgkin Lymphoma, AdultHodgkin Disease RecurrentHodgkin Disease RefractoryHodgkin Disease, PediatricNCT04268706Tessa Therapeutics97
进行中（未招募）
不适用
TRIAL TO ASSESS THE EFFICACY OF LENVATINIB IN METASTATIC NEUROENDOCRINE TUMORS (TALENT STUDY).?EUCTR2015-001467-39-ESGETNE (Grupo Español de Tumores Neuroendocrinos)110
招募中
1 期
A phase 2 study of ianalumab (VAY736) in patients with primary immune thrombocytopenia (ITP) previously treated with at least two lines of therapiesCTIS2022-503041-21-00ovartis Pharma AG40